Paper36960287
Synergistic antifungal interaction of N-(butylcarbamothioyl) benzamide and amphotericin B against Cryptococcus neoformans.
Andriani GM and 16 others. Front Microbiol, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Synergistic antifungal interaction of N-(butylcarbamothioyl) benzamide and amphotericin B against Cryptococcus neoformans. Papers, record 36960287. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36960287
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic antifungal interaction of N-(butylcarbamothioyl) benzamide and amphotericin B against Cryptococcus neoformans.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19151324 | Phylogeny and phenotypic characterization of pathogenic Cryptococcus species and closely related saprobic taxa in the Tremellales. | Eukaryot Cell | 2009 | https://conductscience.org/library/papers/19151324 | PubMed |
| 2 | 35486354 | Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil. | Braz J Microbiol | 2022 | https://conductscience.org/library/papers/35486354 | PubMed |
| 3 | 8592988 | Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/8592988 | PubMed |
| 4 | 11254641 | Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infection. | Infect Immun | 2001 | https://conductscience.org/library/papers/11254641 | PubMed |
| 5 | 33261213 | Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance. | J Fungi (Basel) | 2020 | https://conductscience.org/library/papers/33261213 | PubMed |
| 6 | 35330247 | Deciphering the Association among Pathogenicity, Production and Polymorphisms of Capsule/Melanin in Clinical Isolates of Cryptococcus neoformans var. grubii VNI. | J Fungi (Basel) | 2022 | https://conductscience.org/library/papers/35330247 | PubMed |
| 7 | 35436563 | A holistic review on Cryptococcus neoformans. | Microb Pathog | 2022 | https://conductscience.org/library/papers/35436563 | PubMed |
| 8 | 9593151 | Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9593151 | PubMed |
| 9 | 29906292 | Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH. | PLoS Pathog | 2018 | https://conductscience.org/library/papers/29906292 | PubMed |
| 10 | 30344084 | Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. | Lancet Infect Dis | 2019 | https://conductscience.org/library/papers/30344084 | PubMed |
| 11 | 3814589 | Temperature-dependent modes for the binding of the polyene antibiotic amphotericin B to human erythrocyte membranes. A circular dichroism study. | Biochim Biophys Acta | 1987 | https://conductscience.org/library/papers/3814589 | PubMed |
| 12 | 35496330 | Recent trends in chemistry, structure, and various applications of 1-acyl-3-substituted thioureas: a detailed review. | RSC Adv | 2022 | https://conductscience.org/library/papers/35496330 | PubMed |
| 13 | 33846389 | Design, synthesis and docking studies of novel thiazole derivatives incorporating pyridine moiety and assessment as antimicrobial agents. | Sci Rep | 2021 | https://conductscience.org/library/papers/33846389 | PubMed |
| 14 | 20424328 | Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20424328 | PubMed |
| 15 | 22391546 | Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22391546 | PubMed |
| 16 | 30526466 | Benzoylthioureas: Design, Synthesis and Antimycobacterial Evaluation. | Med Chem | 2020 | https://conductscience.org/library/papers/30526466 | PubMed |
| 17 | 29970809 | Present and Future Therapy of Cryptococcus Infections. | J Fungi (Basel) | 2018 | https://conductscience.org/library/papers/29970809 | PubMed |
| 18 | 12036371 | Molecular properties that influence the oral bioavailability of drug candidates. | J Med Chem | 2002 | https://conductscience.org/library/papers/12036371 | PubMed |
| 19 | 24278784 | Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types. | Scientifica (Cairo) | 2013 | https://conductscience.org/library/papers/24278784 | PubMed |
| 20 | 23333322 | Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. | Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23333322 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42518468 | Novel Inhibitors Targeting Urease Promote Fungicidal and Antivirulence Effects in Cryptococcus. | ACS Omega | 2026 | https://conductscience.org/library/papers/42518468 | PubMed |
| 41018654 | Benzoylselenoureas: A Novel Dual-Action Inhibitor Targeting Fungal Growth and Urease Activity in Cryptococcus neoformans. | ACS Omega | 2025 | https://conductscience.org/library/papers/41018654 | PubMed |
| 40488039 | Molecular Modeling and In Vitro Evaluation of Thioureas and Arylthioureas as Urease Inhibitors. | ACS Omega | 2025 | https://conductscience.org/library/papers/40488039 | PubMed |
| 39885057 | Effects of fluconazole and amphotericin B in the control of cryptococcal pneumonia in vivo. | AMB Express | 2025 | https://conductscience.org/library/papers/39885057 | PubMed |
| 39597712 | Sclareolide as Antifungal Strategy Against Cryptococcus neoformans: Unveiling Its Mechanisms of Action. | Microorganisms | 2024 | https://conductscience.org/library/papers/39597712 | PubMed |
| 39088434 | Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis. | PLoS One | 2024 | https://conductscience.org/library/papers/39088434 | PubMed |
| 37623972 | Antiprotozoal Activity of Benzoylthiourea Derivatives against Trypanosoma cruzi: Insights into Mechanism of Action. | Pathogens | 2023 | https://conductscience.org/library/papers/37623972 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36960287
GET https://conductscience.org/api/papers/v1/36960287/references?page=2